Pfizer Inc. $PFE Stake Lifted by First Bank & Trust

First Bank & Trust lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 21.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 184,140 shares of the biopharmaceutical company’s stock after acquiring an additional 32,523 shares during the quarter. Pfizer comprises about 0.7% of First Bank & Trust’s investment portfolio, making the stock its 24th biggest holding. First Bank & Trust’s holdings in Pfizer were worth $4,585,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Pfizer by 0.9% during the 3rd quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock valued at $7,620,747,000 after purchasing an additional 2,786,098 shares during the period. Norges Bank acquired a new stake in shares of Pfizer in the second quarter valued at $2,270,157,000. Northern Trust Corp boosted its stake in Pfizer by 1.4% during the third quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock valued at $1,631,225,000 after buying an additional 869,175 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Pfizer by 1.9% during the third quarter. Fisher Asset Management LLC now owns 49,288,054 shares of the biopharmaceutical company’s stock worth $1,255,860,000 after acquiring an additional 897,786 shares during the period. Finally, Legal & General Group Plc raised its position in Pfizer by 8.6% in the third quarter. Legal & General Group Plc now owns 41,741,186 shares of the biopharmaceutical company’s stock worth $1,063,565,000 after acquiring an additional 3,296,415 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the company a “positive” rating in a research report on Tuesday, March 17th. Barclays started coverage on shares of Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 target price for the company. BMO Capital Markets restated an “outperform” rating and issued a $30.00 price target on shares of Pfizer in a research report on Monday, March 9th. HSBC increased their price objective on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a research note on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Stock Performance

Pfizer stock opened at $27.29 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.94. The firm’s 50 day simple moving average is $26.78 and its 200-day simple moving average is $25.65. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market cap of $155.16 billion, a P/E ratio of 20.06 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business posted $0.63 EPS. The company’s revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 topline for TALAPRO-3 (TALZENNA + XTANDI) in homologous recombination repair prostate cancer — strengthens Pfizer’s oncology franchise and supports future revenue and labeling opportunities. Pfizer Announces Positive TALAPRO-3 Results
• Positive Sentiment: Guggenheim raised its price target to $36 and upgraded to a buy — a high-profile analyst lift that can drive demand and re-rate the stock if others follow. Benzinga: Guggenheim Raises Price Target
• Positive Sentiment: Analyst and media bullishness on upside from a key prostate‑cancer trial — several write-ups project significant appreciation (examples cite targets near $36) if oncology readouts continue to progress. 247WallSt: Pfizer Could Hit $36
• Positive Sentiment: Coverage highlighting Pfizer as a high‑yield, undervalued play with pipeline catalysts — these narratives attract income and value buyers while emphasizing long‑term upside from new assets. 24/7 Wall St: 6.5% Yielding Dividend Payer
• Positive Sentiment: Pfizer CFO discussed recent oncology milestones on NYSE Live — management visibility on progress helps reduce execution uncertainty and supports investor confidence. Yahoo Finance: CFO Highlights Oncology Milestones
• Neutral Sentiment: Company scheduled a public webcast and analyst call for May 5 to discuss Q1 results and the Q1 performance report — provides a near-term event for updated guidance and pipeline commentary. Yahoo Finance: May 5 Webcast
• Negative Sentiment: Lyme vaccine readout shows ~73% efficacy but missed the trial’s primary statistical target due to low case numbers — clinical/regulatory uncertainty remains and could delay approvals or reduce near-term impact. Yahoo Finance: Pfizer Lyme Vaccine Data
• Negative Sentiment: Competitor momentum: Bristol Myers’ Opdivo label expansions intensify IO competition — pricing and market-share pressure in oncology could constrain long‑term upside for some Pfizer programs. Yahoo Finance: BMY Opdivo Expansion
• Negative Sentiment: Valneva’s stock plunge after mixed Lyme results highlights partner/regulatory risk — market volatility in related vaccine news can spill over to Pfizer sentiment. Yahoo Finance: VALN Mixed Results

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.